Eli Lilly Stock Ticks up After FDA “Breakthrough” Tag for Ovarian Cancer Drug

Cancer drug sofetabart mipitecan earns FDA breakthrough status

The U.S. Food and Drug Administration (FDA) has granted its breakthrough therapy designation to sofetabart mipitecan as a potential treatment for people with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received prior bevacizumab (sold as Avastin, among others) and Elahere (mirvetuximab soravtansine), if eligible. The FDA gives this designation to experimental therapies that have the potential to f…

Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

New York, Jan 20, 2026, 6:50 PM EST — After-hours Eli Lilly’s stock climbed 0.3% to finish Tuesday at $1,041.29, then nudged up another 0.04% in after-hours trading. The boost came after the company announced the U.S. FDA awarded Breakthrough Therapy designation to its ovarian cancer drug candidate, sofetabart mipitecan. (MarketScreener) The shift is modest, yet it resonates as investors continue to bet on Lilly’s pipeline beyond its hit diabete…

FDA Grants BTD to Sofetabart Mipitecan for Platinum-Resistant Ovarian Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Sofetabart mipitecan receives FDA breakthrough therapy designation, showing promising efficacy in treating platinum-resistant ovarian cancer.

FDA Grants Breakthrough Therapy Designation to Sofetabart Mipitecan in PROC

The folate receptor alpha ADC yielded responses, with a favorable safety profile, in patients with high-grade serous ovarian cancer in a phase 1 trial.